PerkinElmer has launched Signals Image Artist software, an image analysis and management platform for drug discovery research. The new offering is designed to help scientists accurately process and analyse their high-content screening (HCS) and cellular imaging data in a matter of hours, versus days or weeks, so they can make… Read More
The latest free-to-listen DDW podcast episode is titled “Recipe for success: collaboration in drug discovery”. It covers three articles written for Volume 22, Issue 2 – Spring 2021 of the Drug Discovery World Magazine, narrated by DDW’s Megan Thomas. These articles are titled: “Why collaboration matters and… Read More
PerkinElmer is providing its PhenoVue Cell Painting Kits to the Joint Undertaking in Morphological Profiling-Cell Painting (JUMP-CP) consortium. The consortium, spearheaded by the Broad Institute of MIT and Harvard and including leading pharmaceutical companies and non-profit research organisations, is focused on creating and sharing the world’s largest, public cell imaging… Read More
The cell painting approach evokes new ideas and strategies for high-content screening (HCS) practitioners to identify new drugs and to study mechanisms of action by leveraging machine learning to measure subtle phenotypic changes at the cellular level. Dr. Alexander Schreiner, HCS Applications Leader, PerkinElmer and Dr. Martin Daffertshofer, High Content… Read More
PerkinElmer has launched the first cell painting kit as part of its new portfolio of PhenoVue cellular imaging reagents. This new range of reagents leverages PerkinElmer’s expertise in cellular imaging and high-content screening and works alongside its microplates, automation, software and high-content screening instruments. With this entire screening workflow, researchers… Read More
